Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
about
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsData interpretation: deciphering the biological function of Type 2 diabetes associated risk loci.The evolving place of incretin-based therapies in type 2 diabetesGlycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Emerging role of insulin with incretin therapies for management of type 2 diabetes.Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.Finding multiple target optimal intervention in disease-related molecular network.Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during RamadanCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.Add-on therapies to metformin for type 2 diabetes.A review of gliptins in 2011.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
P2860
Q26772081-45DD00DF-EC8E-4257-82DB-7BF4BD381319Q30884322-60B405D1-9B16-4989-9CE8-50288D6FE88FQ33866808-24F9A2A5-FF8C-4F76-BB00-FC1F70617F57Q34265490-36D4D3C6-6249-4995-BE73-17CD90108A59Q35214425-EEE2CEFC-19E3-4962-B3D6-1E0E464730D2Q36041081-9A4870C2-F41C-46B8-A24C-2471E9A2BC1BQ37064893-B2EFF687-09CD-411F-80B7-162ACF99A1EBQ37170511-0665FAEE-F564-4A80-81F0-65952D423CB6Q37417767-B45BE64C-A483-410D-80BE-E7332A0A5BFAQ37428857-2696C0F1-6035-411C-B639-0322FA6850FFQ37471910-F46EAA4D-03E6-40D6-BBF0-888D92A984FBQ37818234-646AAEC8-960C-41E2-B6DB-D6794BE2F821Q37965612-22514335-BCAF-4795-A127-DBAB7B694E0DQ37991385-4652B30D-A5C6-468E-83EA-F92B220C034FQ38078436-F1D490DF-5B15-42AF-A7C8-AC8E91562E13Q38082848-B4906029-7C02-4CDF-A120-FBCE17711C0FQ39027188-F2298F3C-B3BF-4524-B814-57BE707AD9ECQ39193265-FD1280D8-B168-403E-BF8D-500D8CE04691Q43034890-17769006-49DE-4567-AAE7-00B3D9C92CDBQ43145231-5818ADCE-2981-479D-8F74-1C142F81104AQ51328925-72711CA3-D146-448A-8D62-601DEA7064E2Q51363561-1D477233-3D8E-49C1-A0C4-DA0CB0218A9BQ51371120-9FDDA51C-3E62-4A9D-9BDC-85CD1F2274E9
P2860
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@ast
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@en
type
label
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@ast
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@en
prefLabel
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@ast
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@en
P2860
P921
P356
P1476
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
@en
P2093
P2860
P304
P356
10.2147/VHRM.S1944
P407
P577
2008-01-01T00:00:00Z